253 related articles for article (PubMed ID: 29165815)
1. Development and validation of a liquid chromatography-tandem mass spectrometry analytical method for the therapeutic drug monitoring of eight novel anticancer drugs.
Herbrink M; de Vries N; Rosing H; Huitema ADR; Nuijen B; Schellens JHM; Beijnen JH
Biomed Chromatogr; 2018 Apr; 32(4):. PubMed ID: 29165815
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous quantification of dabrafenib and trametinib in human plasma using high-performance liquid chromatography-tandem mass spectrometry.
Nijenhuis CM; Haverkate H; Rosing H; Schellens JH; Beijnen JH
J Pharm Biomed Anal; 2016 Jun; 125():270-9. PubMed ID: 27058232
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of a sensitive liquid chromatography tandem mass spectrometry assay for the simultaneous determination of ten kinase inhibitors in human serum and plasma.
Aghai F; Zimmermann S; Kurlbaum M; Jung P; Pelzer T; Klinker H; Isberner N; Scherf-Clavel O
Anal Bioanal Chem; 2021 Jan; 413(2):599-612. PubMed ID: 33155133
[TBL] [Abstract][Full Text] [Related]
4. Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry.
Cardoso E; Mercier T; Wagner AD; Homicsko K; Michielin O; Ellefsen-Lavoie K; Cagnon L; Diezi M; Buclin T; Widmer N; Csajka C; Decosterd L
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Apr; 1083():124-136. PubMed ID: 29544202
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous and rapid determination of 12 tyrosine kinase inhibitors by LC-MS/MS in human plasma: Application to therapeutic drug monitoring in patients with non-small cell lung cancer.
Zhou L; Wang S; Chen M; Huang S; Zhang M; Bao W; Bao A; Zhang P; Guo H; Liu Z; Xie G; Gao J; Wu Z; Lou Y; Fan G
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Jun; 1175():122752. PubMed ID: 33991955
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
Haouala A; Zanolari B; Rochat B; Montemurro M; Zaman K; Duchosal MA; Ris HB; Leyvraz S; Widmer N; Decosterd LA
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jul; 877(22):1982-96. PubMed ID: 19505856
[TBL] [Abstract][Full Text] [Related]
7. Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry.
Lankheet NA; Hillebrand MJ; Rosing H; Schellens JH; Beijnen JH; Huitema AD
Biomed Chromatogr; 2013 Apr; 27(4):466-76. PubMed ID: 22987603
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay quantifying vemurafenib in human plasma.
Nijenhuis CM; Rosing H; Schellens JH; Beijnen JH
J Pharm Biomed Anal; 2014 Jan; 88():630-5. PubMed ID: 24216282
[TBL] [Abstract][Full Text] [Related]
9. Quantification of 11 Therapeutic Kinase Inhibitors in Human Plasma for Therapeutic Drug Monitoring Using Liquid Chromatography Coupled With Tandem Mass Spectrometry.
Herbrink M; de Vries N; Rosing H; Huitema AD; Nuijen B; Schellens JH; Beijnen JH
Ther Drug Monit; 2016 Dec; 38(6):649-656. PubMed ID: 27749781
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of an UPLC-MS/MS method for simultaneous determination of fifteen targeted anti-cancer drugs in human plasma and its application in therapeutic drug monitoring.
Li G; Zhao M; Zhao L
J Pharm Biomed Anal; 2022 Apr; 212():114517. PubMed ID: 35131665
[TBL] [Abstract][Full Text] [Related]
11. Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients.
Reis R; Labat L; Allard M; Boudou-Rouquette P; Chapron J; Bellesoeur A; Thomas-Schoemann A; Arrondeau J; Giraud F; Alexandre J; Vidal M; Goldwasser F; Blanchet B
J Pharm Biomed Anal; 2018 Sep; 158():174-183. PubMed ID: 29883880
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay for the quantification of Dexamphetamine in human plasma.
Herbrink M; Thijssen B; Hillebrand MJX; Rosing H; Schellens JHM; Nuijen B; Beijnen JH
J Pharm Biomed Anal; 2018 Jan; 148():259-264. PubMed ID: 29059615
[TBL] [Abstract][Full Text] [Related]
13. Development and Validation of an LC-MS/MS Method for the Simultaneous Quantification of Abiraterone, Enzalutamide, and Their Major Metabolites in Human Plasma.
van Nuland M; Hillebrand MJX; Rosing H; Schellens JHM; Beijnen JH
Ther Drug Monit; 2017 Jun; 39(3):243-251. PubMed ID: 28490047
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of a rapid LC-MS/MS method to quantify letrozole in human plasma and its application to therapeutic drug monitoring.
Shao R; Yu LY; Lou HG; Ruan ZR; Jiang B; Chen JL
Biomed Chromatogr; 2016 Apr; 30(4):632-7. PubMed ID: 26317321
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous analysis of oral anticancer drugs for renal cell carcinoma in human plasma using liquid chromatography/electrospray ionization tandem mass spectrometry.
Takasaki S; Tanaka M; Kikuchi M; Maekawa M; Kawasaki Y; Ito A; Arai Y; Yamaguchi H; Mano N
Biomed Chromatogr; 2018 Jun; 32(6):e4184. PubMed ID: 29283445
[TBL] [Abstract][Full Text] [Related]
16. Liquid chromatography-tandem mass spectrometry method for simultaneous determination of seven commonly used anticancer drugs in human plasma.
Zhou J; Gao S; Zhang F; Jiang B; Zhan Q; Cai F; Li J; Chen W
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Oct; 906():1-8. PubMed ID: 22959676
[TBL] [Abstract][Full Text] [Related]
17. Development and Validation of a Simultaneous Quantification Method of 14 Tyrosine Kinase Inhibitors in Human Plasma Using LC-MS/MS.
Huynh HH; Pressiat C; Sauvageon H; Madelaine I; Maslanka P; Lebbé C; Thieblemont C; Goldwirt L; Mourah S
Ther Drug Monit; 2017 Feb; 39(1):43-54. PubMed ID: 27861317
[TBL] [Abstract][Full Text] [Related]
18. Investigation of the effect of plasma albumin levels on regorafenib-induced hepatotoxicity using a validated liquid chromatography-tandem mass spectrometry method.
Pang YY; Tan YL; Ho HK
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Sep; 1061-1062():220-224. PubMed ID: 28750235
[TBL] [Abstract][Full Text] [Related]
19. Liquid chromatography-tandem mass spectrometry assay for therapeutic drug monitoring of the tyrosine kinase inhibitor, midostaurin, in plasma from patients with advanced systemic mastocytosis.
Bourget P; Amin A; Chandesris MO; Vidal F; Merlette C; Hirsch I; Cabaret L; Carvalhosa A; Mogenet A; Frenzel L; Damaj G; Lortholary O; Hermine O
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jan; 944():175-81. PubMed ID: 24316764
[TBL] [Abstract][Full Text] [Related]
20. Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC-MS/MS.
Krens SD; van der Meulen E; Jansman FGA; Burger DM; van Erp NP
Biomed Chromatogr; 2020 Mar; 34(3):e4758. PubMed ID: 31758580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
